Clinically, Src activity is increased in invasive breast tumor tissues compared with normal tissue22–24, and the action of Src kinase in integrating both PI3K/Akt and Ras/Raf/ERK signaling pathways25 in cancer progression has made it a potential target for cancer therapeutics. The gene discussed is AKT1; the disease is cancer.